Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Published:2021-05-17 Issue:12 Volume:35 Page:3383-3393
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Dourthe Marie-Emilie,Rabian Florence,Yakouben Karima,Chevillon Florian,Cabannes-Hamy Aurélie,Méchinaud Françoise,Grain Audrey,Chaillou Delphine,Rahal Ilhem,Caillat-Zucman Sophie,Lesprit Emmanuelle,Naudin Jérôme,Roupret-Serzec Julie,Parquet Nathalie,Brignier Anne,Guérin-El Khourouj Valérie,Lainey Elodie,Caye-Eude Aurélie^ORCID,Cavé Hélène^ORCID,Clappier Emmanuelle,Mathis Stéphanie,Azoulay Elie,Dalle Jean Hugues,Dhédin Nathalie,Madelaine Isabelle,Larghero Jérôme,Boissel Nicolas,Baruchel André^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01281-7.pdf

Reference29 articles.

1. Pui C-H, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50:185–96.

2. Boissel N, Baruchel A. Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood. 2018;132:351–61.

3. Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32:2316–25.

4. Locatelli F, Zugmaier G, Bader P, Jeha S, Schlegel P-G, Bourquin J-P, et al. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor and molecularly resistant acute lymphoblastic leukemia (R/R ALL): updated analysis of 110 patients treated in an Expanded Access Study (RIALTO). Blood. 2019;134:1294.

5. Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, et al. Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Leukemia. 2019;33:884–92.

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. The road more or less traveled- Examining the role of consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T cell therapy in B-cell ALL;Seminars in Hematology;2024-08

3. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

4. Les cellules CAR-T ont-elles tenu leurs promesses dans le traitement des leucémies aiguës en 2024 ?;Bulletin de l'Académie Nationale de Médecine;2024-08

5. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma;Frontiers in Immunology;2024-07-19